A partner at Corrs Chambers Westgarth who successfully opposed a genome editing patent by ToolGen, and a corporate predecessor of law firm Ashurst, have been […]
Uber has failed to put the brakes on a massive class action alleging the ride-sharing giant engaged in a conspiracy to steal business from taxi […]
UK biopharmaceutical company Kymab may attack experiments done by US biotechnology giant Regeneron creating genetically modified mice with splices of human genomes, as it defends […]
The Australian Prudential Regulation Authority will not challenge a Federal Court ruling that dismissed its case against fund manager IOOF as âunpersuasiveâ, âfundamentally inadequateâ and […]
The Australian Securities and Investments Commission has won its bid to use evidence from US proceedings in its case against Rio Tinto alleging the mining […]
The prudential regulator is standing by its decision to bring proceedings against IOOF for alleged breaches of superannuation duties, despite criticism that such a “highly […]
APRAâs purely documentary case against troubled fund manager IOOF has been dismissed by the Federal Court as âunpersuasiveâ, âfundamentally inadequateâ and âtenuous in the extremeâ, […]
Pharmaceutical company Generic Health has told the Federal Court that, on advice from their solicitors, Otsuka and Bristol-Myers Squibb “deliberately” chose not to disclose their […]
Otsuka Pharmaceuticals and Bristol Myers-Squibb are seeking to withdraw admissions in patent litigation against Generic Health over anti-psychotic drug Abilify, following a landmark ruling last […]
The operator of a Vietnamese mine has dropped its Federal Court proceedings against WorleyParsons subsidiary Jacobs E&C over the enforcement of a $132 million arbitration […]